by EpicentRx | May 7, 2024 | Conferences
May 31-June 4, 2024 – Chicago, Illinois Oral Presentation: Phase 1/2 study of the TGF-β-trap-enhanced oncolytic adenovirus, AdAPT-001, plus an immune checkpoint inhibitor for patients with immune refractory cancers. Learn more
by EpicentRx | May 7, 2024 | Conferences, General
April 2024 – Long Beach, California Learn more
by EpicentRx | May 7, 2024 | Conferences
April 2024 – San Diego, California Poster Session: Improved clinical outcomes in patients received treatment beyond tumor progression with AdAPT-001 +/- a checkpoint inhibitor Learn more
by EpicentRx | May 7, 2024 | Media
